10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. KFY
5. ABBV
6. MU
7. DPZ
8. NAVN
9. DFTX
10. NVEC

Go back to 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

10X Genomics (TXG) PT Lowered to $20 at Citi

February 13, 2025 6:40 AM EST

Citi analyst Patrick Donnelly lowered the price target on 10X Genomics (NASDAQ: TXG) to $20.00 (from $23.00) while maintaining a Buy rating.

The analyst comments "After pre-announcing last month, TXG reported official 4Q revenue of $165mn, above FactSet consensus of ~$160mn and the... More